"IntraBio Announces Positive Pivotal Trial Results of IB1001 for the Treatment of Niemann-Pick Disease Type C"
Read the full article here:
IB1001 showed a clinically meaningful improvement in symptoms, functioning, quality of life, and cognition in both pediatric and adult patients with NPC
IB1001 was safe and well-tolerated with a favorable safety profile consistent with previous clinical and pre-clinical studies
Based on these positive results, IntraBio plans to file for marketing authorization with IB1001 with the FDA and EMA
To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."
Ways to support NP-C in Australia: